What is (C) D-V14 used for?

(C) D-V14 is indicated for Atrial fibrillation for stroke prevention.

(C) D-V14 is developed by National Taiwan University Hospital.

What development phase is (C) D-V14 in?

(C) D-V14 is FDA-approved (marketed).

What are the side effects of (C) D-V14?

Common side effects include QT interval prolongation, Bradycardia.

Last reviewed 2026-04-23 · How we verify

(C) D-V14

National Taiwan University Hospital · FDA-approved active Small molecule

D-V14 is a medication used to treat atrial fibrillation.

D-V14 is a medication used to treat atrial fibrillation. Used for Atrial fibrillation for stroke prevention.

At a glance

Generic name	(C) D-V14
Sponsor	National Taiwan University Hospital
Drug class	Antiarrhythmic
Target	Potassium channels
Modality	Small molecule
Therapeutic area	Cardiovascular
Phase	FDA-approved

Mechanism of action

It works by blocking potassium channels in the heart, which helps to regulate heart rhythm. This can reduce the risk of stroke and other complications associated with atrial fibrillation.

Approved indications

Atrial fibrillation for stroke prevention

Common side effects

QT interval prolongation
Bradycardia

Key clinical trials

Comparison of Vonoprazan-based Versus Lansoprazole-based Triple Therapy, High Dose Dual Therapy, Bismuth and Non-bismuth Quadruple Therapy in the First-line Treatment of Helicobacter Pylori Infection (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results